Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The partnership also sets the stage for broader collaboration on rare disease treatments
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Subscribe To Our Newsletter & Stay Updated
